GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » Ending Cash Position

Cencora (Cencora) Ending Cash Position : $2,285 Mil (As of Mar. 2024)


View and export this data going back to 1995. Start your Free Trial

What is Cencora Ending Cash Position?

Cencora's Ending Cash Position for the quarter that ended in Mar. 2024 was $2,285 Mil.

Cencora's quarterly Ending Cash Position increased from Sep. 2023 ($2,753 Mil) to Dec. 2023 ($3,036 Mil) but then declined from Dec. 2023 ($3,036 Mil) to Mar. 2024 ($2,285 Mil).

Cencora's annual Ending Cash Position increased from Sep. 2021 ($3,070 Mil) to Sep. 2022 ($3,594 Mil) but then declined from Sep. 2022 ($3,594 Mil) to Sep. 2023 ($2,753 Mil).

Cencora Ending Cash Position Historical Data

The historical data trend for Cencora's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cencora Ending Cash Position Chart

Cencora Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,374.19 4,597.75 3,070.13 3,593.54 2,752.89

Cencora Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,688.66 1,548.25 2,752.89 3,036.12 2,285.15

Cencora Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Cencora's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=3593.539+-840.65
=2,753

Cencora's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=3036.121+-750.975
=2,285

Cencora Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Cencora's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Cencora (Cencora) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Cencora Inc (NYSE:COR) » Definitions » Ending Cash Position
Comparable Companies
CAH MCK HSIC PDCO OMI ZYXI EDAP AHG YI COSM HKSE:01099 SHSE:601607 MIL:AMP NZSE:EBO XSWX:GALE SHSE:600511 TSE:7459 SZSE:000028 TSE:2784 TSE:9987
Traded in Other Exchanges
ABG:Germany C1CO34:Brazil ABC:Austria
Address
1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Website
https://www.cencora.com
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the U.S. pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Executives
Leslie E Donato officer: EVP & Chief Strategy Officer 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Elizabeth S Campbell officer: Executive Vice President 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Steven H Collis officer: President & CEO 1300 MORRIS DRIVE, SUITE 100, CHESTERBROOK PA 19087
Lazarus Krikorian officer: Senior Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Silvana Battaglia officer: Executive Vice President 227 WASHINGTON STREET, CONSHOHOCKEN PA 19428
Walgreens Boots Alliance, Inc. 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Gina Clark officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Werner Baumann director 1 WEST FIRST AVENUE, CONSHOHOCKEN PA 19428
Lauren M Tyler director C/O ALLEGHANY CORPORATION, 1411 BROADWAY, 34TH FLOOR, NEW YORK NY 10018
Robert P. Mauch officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087
Redonda Miller director 303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Lorence H. Kim director C/O SERES HEALTH, INC., 161 FIRST STREET, CAMBRIDGE MA 02472
Walgreens Boots Alliance Holdings Llc 10 percent owner 108 WILMOT ROAD, DEERFIELD IL 60015
Lon R Greenberg director 460 NORTH GULPH ROAD, KING OF PRUSSIA PA 19406
John G. Chou officer: Executive Vice President 1300 MORRIS DRIVE, CHESTERBROOK PA 19087